Rhythm Pharmaceuticals

RYTM Rare disease Lead: Approved 9 Biotech Distilled articles ↓

Most recent annual filing: 2026-02-15

Catalyst timeline

Bivamelagon Ph3 start2026Bivamelagon Ph3 start, 2026, routine
Setmelanotide HO commercial launch4Q 2026Setmelanotide HO commercial launch, 4Q 2026, notable
HO launch metrics commercial4Q 2026HO launch metrics commercial, 4Q 2026, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (13 active programs)

IMCIVREE

setmelanotide

Peptide Target: MC4R

Bardet-Biedl Syndrome Approved subcutaneous NCT03746522
POMC Deficiency Obesity Approved subcutaneous NCT02896192
LEPR Deficiency Obesity Approved subcutaneous
Acquired Hypothalamic Obesity Approved subcutaneous
Congenital Hypothalamic Obesity Phase 3 subcutaneous
Prader-Willi Syndrome Phase 2 subcutaneous NCT02311673
POMC Insufficiency Obesity Phase 3 subcutaneous
LEPR Insufficiency Obesity Phase 3 subcutaneous
SRC1 Deficiency Obesity Phase 3 subcutaneous
SH2B1 Deficiency Obesity Phase 3 subcutaneous

bivamelagon

LB54640

Small Molecule Target: MC4R

Acquired Hypothalamic Obesity Phase 2 oral NCT06046443

RM-718

Peptide Target: MC4R

Acquired Hypothalamic Obesity Phase 1 Phase 1/2 trial subcutaneous NCT06239116
Prader-Willi Syndrome Phase 1 subcutaneous NCT06239116

Biotech Distilled coverage (9)

2026-08-24 UPDATE: Rhythm Pharmaceuticals (RYTM) - Japan Says Yes, and the Last Regulatory Domino Falls
2026-08-05 UPDATE: Rhythm Pharmaceuticals (RYTM) - The Launch Converts, and RM-718 Clears the Bar 🔒 Paid
2026-06-15 UPDATE: Rhythm Pharmaceuticals (RYTM) - The ENDO Data Dump and the PWS Reality Check
2026-05-06 UPDATE: Rhythm Pharmaceuticals (RYTM) - The Launch Metric That Flipped the Script 🔒 Paid
2026-03-29 UPDATE: Rhythm Pharmaceuticals (RYTM) - The CHMP Gives a Green Light, but the ATM Hangover Persists 🔒 Paid
2026-03-22 UPDATE: Rhythm Therapeutics (RYTM) - The Agony, The Ecstasy, and The P-Hacking Reality Check 🔒 Paid
2026-03-07 UPDATE: Rhythm Therapeutics (RYTM) - Final TRANSCEND Data Drop Cements the HO Thesis Ahead of PDUFA 🔒 Paid
2026-02-28 RYTM Update: Dissecting the Earnings, the Oral Pipeline, and the Wall of Paper 🔒 Paid
2026-01-19 Rhythm Therapeutics (RYTM): Scientific Deep Dive for Setmelanotide and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.